UNSPSC 51152062: Mephenesin carbamate

This classification denotes a muscle relaxant with the molecular formula C11H15NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PAD6SXB23N, chemically known as 1,2-propanediol, 3-(o-tolyloxy)-, 1-carbamate (8ci) but more generally known as mephenesin carbamate, which bears US NIH Compound Identifier 10775. Most nations, for tariff and trade purposes, schedule mephenesin carbamate under HS 29094990 and SITC 51617. As of Q4 2014, MEPHENESIN CARBAMATE remains US FDA's Preferred Term for this commodity. SMILES: CC1CCCCC1OCC(COC(=O)N)O.

UNSPSC 51152062 Mephenesin carbamate, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal pharmaceutical scope. The code nominally describes a specific muscle relaxant compound, but recent opportunities tagged under it diverge significantly from this narrow definition. State and local governments do solicit pharmaceutical and health-support products through competitive bidding, but the two recent opportunities on record — Seminole County's procurement of naloxone and drug deactivation systems, and Texas HHS's Request for Information on direct-to-manufacturer prescription programs — address opioid-overdose response and pharmacy benefit management rather than mephenesin carbamate itself. The issuing bodies include county health departments and state health-and-human-services agencies, reflecting the broader landscape of state and local pharmaceutical procurement.

Geographic activity concentrates in Florida and Texas based on recent postings. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, expecting quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription programs without a formal evaluation period. The code's recent-opportunity record suggests a mismatch between its pharmaceutical-compound definition and the actual health-procurement category it represents in state and local solicitations; firms pursuing this code should expect broader pharmaceutical-product and pharmacy-benefit categories rather than the specific compound the UNSPSC label names.